Northeastern University and Harvard Medical School

报告摘要：
Rapid, accurate, continuous, and quantitative measurement of biomarkers from body fluids are critical for non-invasive assessment of clinical status of various metabolic disorders to improve disease management and clinical progress. The goal of this Bioengineering Consortium is to develop multiplexed sensors that use a drop of blood or urine (> 10 micro L) and quantify more than one clinically important analyte simultaneously and answer specific questions for diagnosis or research. The small sample size means that the devices can be used at the bedside, home, or laboratory. The proposed multiplexed sensor makes several measurements simultaneously which are analyzed together to determine a specific result with greater precision than a single sensor and more efficiently than a series of individual tests. We have found several clinical research programs that are extremely interested in this approach, even though it is different than the standard model for clinical care where physicians rely on data collected from a list of separate individual tests to determine a diagnosis. Personalized, Precision Medicine requires extremely sensitive POC devices and systems. The fundamental technology proposed for the multiplexed sensor platform is a new electronic biosensor platform technology based on two-dimensional (2D) atomically layered materials (such as graphene, doped graphene and molybdenum disulphide- MoS2) in combination with high sensitivity electrical impedance spectroscopic (FET) readout. These 2D-FET sensors combine the exceptional electrical properties of emerging atomically thin planar nanomaterials, the selectivity of proteins and other targets, and low-cost fabrication to offer new diagnostic tools with much greater precision. Organ on a Chip, Pancreas, are embedded in flexible polymeric sheets, wearable, screen printable for large scale manufacturing. The Bioenginering Consortium has demonstrated biosensors that use enzymes, antibodies, and single-stranded mRNAs and microRNAs for molecular recognition and sensing. These sensors will be evaluated at Children’s Hospital in Boston, Mayo Clinic, Brigham and Women’s Hospital with the collaboration of clinical collaborators and physicians.

报告人简介：
Prof. V. Renugopalakrishnan, American Biophysicist. “Renu” and his group at the Children’s Hospital / Harvard Medical School and Northeastern University focuses on the interface between protein engineering and nanotechnology. He has been on Harvard faculty since 1984, starting from Assistant Professor to a Professor. In recent years his laboratory has been targeting proteins as intelligent and innovative biomaterials in solar cells, fuel cells, very high density data storage, and tagged on to CNT/Graphene for directed drug delivery, sensors. He obtained his B.Sc. from the Madras University, entered graduate school in the Dept. of Chemistry, Columbia University, New York, NY and Rockefeller University, New York, NY working with Prof Harold C Urey, Nobel Chemistry Laureate and Prof. Barbara Low and obtained his Ph.D. in Biophysical Sciences from State University of New York, Buffalo, New York. He is the author of more than 250 publications, and member of academies. He was the Editor in-Chief, Journal of Bionanoscience, Associate Editor, Journal of Nanoscience and Nanotechnology and serves on 6 Editorial Boards of Journals.

邀请人： 吴克辉 研究员（电话：82648130）
联系人： 朱学涛 副研究员（电话：82649008）